Stacy Lindborg; Independent Director; Imunon Inc. Presentation. Operator. Good morning. My name is Mike, and I will be your operator today. At this time, I would lik ...

Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...

Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant ...

Ended 2024 with $5.9M in cash and cash equivalents. The company believes it has sufficient capital resources to fund its operations into late ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Verizon Innovative Learning, an award-winning education initiative, has reached ...

New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...